MX2019011987A - Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos. - Google Patents

Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos.

Info

Publication number
MX2019011987A
MX2019011987A MX2019011987A MX2019011987A MX2019011987A MX 2019011987 A MX2019011987 A MX 2019011987A MX 2019011987 A MX2019011987 A MX 2019011987A MX 2019011987 A MX2019011987 A MX 2019011987A MX 2019011987 A MX2019011987 A MX 2019011987A
Authority
MX
Mexico
Prior art keywords
compounds
gsk3
glycogen synthase
synthase kinase
kinases
Prior art date
Application number
MX2019011987A
Other languages
English (en)
Spanish (es)
Inventor
Teyu Chen
Florence Fevrier Wagner
Michel Weiwer
Campbell Arthur J
Joshua R Sacher
Edward Holson
Brian Stuart Lucas
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of MX2019011987A publication Critical patent/MX2019011987A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019011987A 2017-04-05 2018-04-05 Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos. MX2019011987A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481981P 2017-04-05 2017-04-05
PCT/US2018/026339 WO2018187630A1 (en) 2017-04-05 2018-04-05 Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011987A true MX2019011987A (es) 2020-07-14

Family

ID=63712671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011987A MX2019011987A (es) 2017-04-05 2018-04-05 Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos.

Country Status (14)

Country Link
US (2) US11203601B2 (enExample)
EP (1) EP3606528B1 (enExample)
JP (1) JP7157075B2 (enExample)
KR (1) KR20190136063A (enExample)
CN (1) CN110958882B (enExample)
AU (1) AU2018249558A1 (enExample)
BR (1) BR112019020810A2 (enExample)
CA (1) CA3058198A1 (enExample)
CO (1) CO2019012324A2 (enExample)
EA (1) EA201992359A1 (enExample)
IL (1) IL269701A (enExample)
MX (1) MX2019011987A (enExample)
SG (1) SG11201909115WA (enExample)
WO (1) WO2018187630A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096594B2 (en) 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
WO2018187630A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
CN119053690A (zh) * 2022-06-20 2024-11-29 上海优替济生生物医药有限公司 体外诱导干细胞样记忆细胞的化合物及其应用
AU2024269298A1 (en) 2023-05-10 2025-11-27 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024259178A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
AU690906B2 (en) 1993-04-08 1998-05-07 Du Pont Pharmaceuticals Company Novel polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disoders
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
EP1355909A2 (en) 2001-02-02 2003-10-29 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
RS51351B (sr) 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-dihidropiridin-kondenzovani hterocikli, postupci za njihovo dobijanje, upotreba i kompozicije koje ih sadrže
WO2008016123A1 (en) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US9265764B2 (en) 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
US9096594B2 (en) 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
KR20170044144A (ko) * 2014-09-05 2017-04-24 메르크 파텐트 게엠베하 암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물
WO2018187630A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2018187630A1 (en) 2018-10-11
KR20190136063A (ko) 2019-12-09
EP3606528A1 (en) 2020-02-12
US12486289B2 (en) 2025-12-02
CN110958882B (zh) 2023-08-29
WO2018187630A8 (en) 2019-01-03
CA3058198A1 (en) 2018-10-11
CN110958882A (zh) 2020-04-03
US20220112216A1 (en) 2022-04-14
IL269701A (en) 2019-11-28
AU2018249558A1 (en) 2019-11-07
JP7157075B2 (ja) 2022-10-19
EA201992359A1 (ru) 2020-03-12
SG11201909115WA (en) 2019-10-30
BR112019020810A2 (pt) 2020-04-28
CO2019012324A2 (es) 2020-05-15
JP2020516616A (ja) 2020-06-11
EP3606528A4 (en) 2020-12-23
EP3606528B1 (en) 2023-10-18
US11203601B2 (en) 2021-12-21
US20200109154A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
MX2019011987A (es) Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos.
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
MX2020004699A (es) Derivados de pirimidina como inhibidores de la activacion de pd1/pd-l1.
CL2016002942A1 (es) Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1
CR10136A (es) Nucleósidos antivirales
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
TN2010000131A1 (en) Polo-like kinase inhibitors
NZ803738A (en) Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
MX2018003058A (es) Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
PE20161443A1 (es) Compuestos
MX389825B (es) Compuestos y composiciones para tratar trastornos hematologicos.
UY31892A (es) Fosfatos ciclicos de nucleosidos
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
CO6190519A2 (es) Compuestos y metodos para modulacion de cinasa e indicaciones para ello
CO6400228A2 (es) Sintesis de nucleosidos de purina
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
UY35361A (es) COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
DOP2009000073A (es) Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp.
CL2012000003A1 (es) Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer.
MX387359B (es) Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
ECSP088194A (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos